Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.97 USD

201.97
2,701,007

+1.50 (0.75%)

Updated Nov 5, 2024 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

The Zacks Analyst Blog Highlights: AbbVie, Eagle Bancorp Montana, H&R Block, Mackinac Financial and Virtu Financial

The Zacks Analyst Blog Highlights: AbbVie, Eagle Bancorp Montana, H&R Block, Mackinac Financial and Virtu Financial

5 Defensive Stocks to Buy as Coronavirus Cases Rise Again

An alarming rise in the number of coronavirus cases results in volatility in the market and raises the appeal of defensive stocks

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals

J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.

Go Defensive to Beat Market Turbulence With These 4 Stocks

Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.

Sejuti Banerjea headshot

6 Defensive Stocks to Beat the Volatility

Low-beta dividend paying names may be the best way to go in a volatile market.

AbbVie Inks Deal With Genmab, Announces ADC Candidate Data

AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.

AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?

AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Top Ranked Value Stocks to Buy for June 11th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 11th

Vertex's Kalydeco Wins Approval in EU for CF in Children

Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.

Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks

Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $94.59, marking a +0.79% move from the previous day.

Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication

The FDA approves Merck's (MRK) sNDA seeking approval for its antibacterial injection Recarbrio regarding a new indication. The application was filed in February 2020.

AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment

AbbVie (ABBV) collaborates with three parties for developing an antibody-based treatment for COVID-19.

3 Top Dividend Stocks to Maximize Your Retirement Income - June 08, 2020

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Powerful Proof Anyone Can Invest for an Early Retirement - June 08, 2020

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

Silgan, Canada Goose, Sempra Energy, Fortinet and Abbvie highlighted as Zacks Bull and Bear of the Day

Silgan, Canada Goose, Sempra Energy, Fortinet and Abbvie highlighted as Zacks Bull and Bear of the Day

Nalak Das headshot

4 Reasons Why Wall Street's V-Shaped Recovery Should Continue

Reopening of the economy and recently released better-than expected economic data strengthened investors' confidence in U.S. stocks.

The Zacks Analyst Blog Highlights: AbbVie, Amkor Technology, Calix, The Hain Celestial Group and Acacia Communications

The Zacks Analyst Blog Highlights: AbbVie, Amkor Technology, Calix, The Hain Celestial Group and Acacia Communications

Kinjel Shah headshot

Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals

Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.

John Blank headshot

A "Don't Fight the Fed" Rally: Zacks June Strategy

In early May, international travel shutdowns remained the norm. Some U.S. state governors gingerly lifted their "Stay-at-Home" decrees. In early June, a number of European travel shutdowns are ending, and all 50 U.S. states are open for business.

Is AbbVie (ABBV) Outperforming Other Medical Stocks This Year?

Is (ABBV) Outperforming Other Medical Stocks This Year?

Novartis (NVS) Announces Positive Data From Cosentyx Study

Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.

Signs That Your Trading Will Ruin Your Retirement - June 04, 2020

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.